头痛患者接种 COVID-19 疫苗后的头痛发生率：一项横断面研究。
Incidence of headache after COVID-19 vaccination in patients with history of headache: A cross-sectional study.
机构信息
Department of Neurology, Keio University School of Medicine, Tokyo, Japan.
Biostatistics Unit, Clinical and Translational Research Center, Keio University Hospital, Tokyo, Japan.
出版信息
Cephalalgia. 2022 Mar;42(3):266-272. doi: 10.1177/03331024211038654. Epub 2021 Aug 18.
BACKGROUND
Headache is an adverse event of coronavirus 2019 (COVID-19) vaccination. Whether patients with history of headache suffer more from vaccination-induced headaches is unknown. We aimed to uncover if headache patients develop more headaches after COVID-19 mRNA vaccination than healthy controls.
METHODS
We performed a questionnaire survey for nursing staff in our hospital from April to May 2021. Based on baseline characteristics, we divided the participants into migraine, non-migrainous headache, and healthy control, and examined the occurrence and features of headache after COVID-19 vaccinations.
RESULTS
We included 171 participants (15.2% migraine and 24.6% non-migrainous headache). Headache incidence after vaccinations was significantly higher in the migraine (69.2%) and non-migrainous headache (71.4%) groups than in the healthy control (37.9%) group. The incidence of headaches was significantly higher after the second dose compared to the first (45.6% vs. 20.5%).
CONCLUSION
Migraineurs and non-migrainous headache participants developed more headaches compared to the healthy controls after COVID-19 vaccination.
背景
头痛是新型冠状病毒 2019（COVID-19）疫苗接种的不良反应。既往有头痛史的患者在接种疫苗后是否更容易发生头痛尚不清楚。我们旨在揭示 COVID-19 mRNA 疫苗接种后头痛患者比健康对照组发生更多头痛的情况。
方法
我们于 2021 年 4 月至 5 月对我院护理人员进行问卷调查。根据基线特征，我们将参与者分为偏头痛、非偏头痛性头痛和健康对照组，并检查 COVID-19 疫苗接种后头痛的发生和特征。
结果
我们共纳入 171 名参与者（15.2%为偏头痛，24.6%为非偏头痛性头痛）。偏头痛（69.2%）和非偏头痛性头痛（71.4%）组接种疫苗后的头痛发生率明显高于健康对照组（37.9%）。与第一剂相比，第二剂后头痛发生率明显更高（45.6% vs. 20.5%）。
结论
与健康对照组相比，COVID-19 疫苗接种后偏头痛和非偏头痛性头痛患者发生更多头痛。
Zotero 插件